Skip to Content

Fosrenol Side Effects

Generic Name: lanthanum carbonate

Note: This page contains information about the side effects of lanthanum carbonate. Some of the dosage forms included on this document may not apply to the brand name Fosrenol.

Not all side effects for Fosrenol may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to lanthanum carbonate: oral powder, oral tablet chewable

In addition to its needed effects, some unwanted effects may be caused by lanthanum carbonate (the active ingredient contained in Fosrenol). In the event that any of these side effects do occur, they may require medical attention.

You should check with your doctor immediately if any of these side effects occur when taking lanthanum carbonate:

Incidence not known
  • Bone pain
  • convulsions
  • difficulty having a bowel movement (stool)
  • itching skin or rash
  • loss of appetite
  • trouble breathing
  • unusual tiredness or weakness

If any of the following symptoms of overdose occur while taking lanthanum carbonate, get emergency help immediately:

Symptoms of overdose
  • Headache
  • nausea
  • vomiting

Some of the side effects that can occur with lanthanum carbonate may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

More common
  • Abdominal or stomach pain
Incidence not known
  • Belching
  • heartburn
  • indigestion
  • stomach discomfort or upset
  • tooth injury

For Healthcare Professionals

Applies to lanthanum carbonate: oral powder for reconstitution, oral tablet chewable

General

The most common adverse reactions included nausea, vomiting, and abdominal pain.[Ref]

Gastrointestinal

Nausea, diarrhea, and vomiting occurred more frequently among patients taking the oral powder formulation than those receiving the chewable tablets (18% versus 7%).[Ref]

Very common (10% or more): Nausea (up to 37%), vomiting (up to 27%), diarrhea (up to 24%), abdominal pain (up to 17%), constipation (up to 15%)
Common (1% to 10%): Dyspepsia, flatulence
Uncommon (0.1% to 1%): Gastroenteritis, eructation, indigestion, irritable bowel syndrome, dry mouth, stomatitis, loose stools, esophagitis, tooth disorder
Postmarketing reports: Tooth injury chewing the tablet[Ref]

Metabolic

Common (1% to 10%): Hypocalcemia
Uncommon (0.1% to 1%): Hypercalcemia, hyperglycemia, hyperphosphatemia, hypophosphatemia, anorexia, appetite increased, thirst[Ref]

Respiratory

Common (1% to 10%): Bronchitis, rhinitis
Uncommon (0.1% to 1%): Laryngitis[Ref]

Endocrine

Uncommon (0.1% to 1%): Hyperparathyroidism[Ref]

Serum parathyroid concentrations may fluctuate depending on a patient's serum calcium, phosphate and vitamin D status. This drug has not been shown to have any direct effects on PTH secretion.[Ref]

Hypersensitivity

Postmarketing reports: Allergic skin reactions (skin rashes, urticaria, and pruritus)[Ref]

Musculoskeletal

The effects of this drug on the bones of patients undergoing dialysis have been evaluated in studies of up to 4.5 years duration. Compared with standard treatments including calcium carbonate, no differences in adverse effects on the musculoskeletal system, including fractures, were observed.[Ref]

Uncommon (0.1% to 1%): Arthralgia, myalgia, osteoporosis[Ref]

Dermatologic

Uncommon (0.1% to 1%): Alopecia, increased sweating[Ref]

Other

Uncommon (0.1% to 1%): Vertigo, asthenia, fatigue, malaise[Ref]

Cardiovascular

Uncommon (0.1% to 1%): Chest pain, peripheral edema[Ref]

Hematologic

Uncommon (0.1% to 1%): Eosinophilia[Ref]

Nervous system

Very common (10% or more): Headache (up to 22%)
Uncommon (0.1% to 1%): Dizziness, taste alteration[Ref]

Renal

Very common (10% or more): Dialysis graft occlusion (up to 25%)[Ref]

References

1. Cerner Multum, Inc. "Australian Product Information." O 0

2. "Product Information. Fosrenol (lanthanum carbonate)." Shire US Inc, Florence, KY.

3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide